From the ∗Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
†College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, China
‡Department of Nuclear Medicine, Fujian Provincial Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
§Department of Radiology, University of Pennsylvania, Philadelphia, PA.
Received for publication August 29, 2022; revision accepted November 24, 2022.
Conflicts of interest and sources of funding: H.F.K. is the founder of Five Eleven Pharma, which holds the patent rights for 68Ga-P16-093 and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose. This study was supported by the Chinese Academy of Medical Science Innovation Fund for Medical Sciences (2021-I2M-1-016, 2022-I2M-2-002), Beijing Natural Science Foundation (M22035), and the National Natural Science Foundation of China (81871392).
G.W. and L.L. contributed equally to this work.
Correspondence to: Zhaohui Zhu, MD, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China. E-mail: [email protected]; Hank F. Kung, PhD, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104. E-mail: [email protected]; Lin Zhu, PhD, College of Chemistry, Beijing Normal University, Beijing 100875, China. E-mail: [email protected].
